Let us be the generation that stands up to cytomegalovirus (CMV), a highly contagious viral infection that can harm an unborn child. Learn more about a clinical trial for a potential vaccine.
ictory Trial
This clinical trial is sponsored by Moderna. Moderna is studying mRNA-1647, an investigational
vaccine to understand whether it can help your immune system protect against cytomegalovirus (CMV).
The purpose of this clinical trial is to:
Cytomegalovirus, shortened to CMV, is a leading cause of birth defects around the world. CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to suffer long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against CMV.
The total length of participation in this clinical trial is
approximately 2½ years (30 months).
You will be compensated for your time and for each visit you complete. More information about
reimbursement can be found in the expenses section of the Patient Information and Informed Consent Form,
and your clinical trial team can also give you more details.
We will schedule your visits in a way that minimizes disruption to your work and other commitments.
The investigational vaccine may help the body's immune system recognize and protect itself if it comes into contact with CMV in the future. You cannot become infected with CMV from receiving the investigational vaccine. The investigational vaccine in this trial, mRNA-1647, is a newer type of vaccine known as an mRNA vaccine.
Map:
Every virus has signature features on its surface that can trigger your immune
system. Once the features are mapped, an mRNA vaccine provides the blueprint to create the defense that
can help your body protect itself if it encounters the virus.
Read:
Once your body has the blueprint, it knows exactly what to do. It reads mRNA
strands to build a defense by producing antibody proteins that are a lot like the answer key to a test.
This means the next time your immune system encounters this type of virus, it already has the answer to
help protect you.
Neutralize:
Your body now knows how to neutralize the virus and is able to defend
itself against the threat if it encounters the virus in the future. The message from the blueprint that
was read is retained and recalled when needed. It's like remembering the answer from an old test without
having to re-learn the material.
Activate:
Moderna is developing mRNA vaccines, like the investigational vaccine
mRNA-1647, that deliver blueprints to create the proteins that help activate immune responses against
a variety of viruses.
The investigational vaccine may help the body's immune system recognize and protect itself if it comes into contact with CMV in the future. You cannot become infected with CMV from receiving the investigational vaccine. The investigational vaccine in this trial, mRNA-1647, is a newer type of vaccine known as an mRNA vaccine.
Map:
Every virus has signature features on its surface that can trigger your immune
system. Once the features are mapped, an mRNA vaccine provides the blueprint to create the defense that
can help your body protect itself if it encounters the virus.
Read:
Once your body has the blueprint, it knows exactly what to do. It reads mRNA
strands to build a defense by producing antibody proteins that are a lot like the answer key to a test.
This means the next time your immune system encounters this type of virus, it already has the answer to
help protect you.
Neutralize:
Your body now knows how to neutralize the virus and is able to defend
itself against the threat if it encounters the virus in the future. The message from the blueprint that
was read is retained and recalled when needed. It's like remembering the answer from an old test without
having to re-learn the material.
Activate:
Moderna is developing mRNA vaccines, like the investigational vaccine
mRNA-1647, that deliver blueprints to create the proteins that help activate immune responses against
a variety of viruses.
Vaccines aim to safely protect people against infections, and clinical trials are vital to creating vaccines. A clinical Trial can help researchers understand whether an investigational vaccine is safe and effective. By participating in the CMVictory Trial, you can help create a future where we may hopefully declare victory and prevent the spread of CMV.
Moderna is committed to keeping people at the center of everything we do as we continue to explore what is possible through mRNA science. Without people like you, researching potential new treatments and mRNA vaccines would not be possible.
We are proud to partner with the following groups and organizations in the fight for victory against CMV:
Clinical trial staff will explain any additional requirements and answer any questions you or a loved one may have about participation. You may stop participation in the clinical trial at any time, and you do not have to give a reason for doing so.
Moderna is committed to researching safe and effective mRNA-based vaccines and therapies to bring better health and living to people of all ages, sexes, and backgrounds.
The CMVictory Trial will take place at locations (or sites) all around the world. Use this site locator to search for the site closest to you—as well as their contact information.
